Prescriber Insights: Navigating FDA Updates on Semaglutide & Tirzepatide for Clinicians

Описание: FDA Regulatory Changes for Semaglutide & Tirzepatide – What Prescribers Must Know!

Join Frier Levitt attorneys Arielle Miliambro and Martha Rumore as they provide a comprehensive breakdown of recent FDA updates on semaglutide and tirzepatide, key compounding regulations, and legal considerations for clinicians.

What You’ll Learn:
• Understanding the FDA’s New Guidance on Compounded GLP-1s
o What the removal from the shortage list means for compounding pharmacies
o Key regulatory changes impacting prescribing and dispensing
• How Providers Can Continue Writing for Compounded Semaglutide & Tirzepatide
o Legal pathways and compliance considerations for ongoing patient care
o Strategies for ensuring access while adhering to FDA regulations
• Ensuring Compliance & Best Practices for Optimizing Patient Health
o Key steps providers must take to remain compliant
o Navigating pharmacy partnerships and prescription protocols effectively

Presented by Frier Levitt Attorneys:
• Arielle Miliambro, Esq.
• Martha M. Rumore, PharmD, Esq., MS, LLM, FAPhA

📅 Recorded Date: March 17, 2025

👉 Subscribe for more updates on compounding, legal insights, and regulatory changes!

Have questions? Contact Frier Levitt’s legal team for guidance.

#503ACompounding #GLP1Regulations #PharmacyLaw #HealthcareLaw #FDARegulations #GLP1Compounding #Semaglutide #Tirzepatide